SBIR Phase I: Biochemical Modulation of Resident Skeletal Stem Cells for In Vivo Hyaline Cartilage Regeneration

Award ID: 2604938

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in addressing one of the most widespread and costly health conditions affecting society: the loss of cartilage that leads to joint degeneration and osteoarthritis. Cartilage injuries and early stage osteoarthritis affect millions of individuals and often progress to disability, pain, and the need for invasive joint replacement surgery. Current treatment options do not regenerate true cartilage, leaving a major unmet medical need. This project aims to develop a minimally invasive, one step therapeutic approach that restores healthy cartilage by activating the bodys own regenerative capacity. If successful, this technology could reduce long term healthcare costs, delay or prevent joint replacement surgeries, improve mobility, and enhance quality of life for a broad patient population. The project also supports economic growth by advancing a new regenerative medicine platform with potential applications in sports medicine, military medicine, and veterinary care. This Small Business Innovation Research (SBIR) Phase I project seeks to develop a therapeutic strategy that enables the regeneration of native hyaline cartilage by guiding the activity of skeletal stem cells that reside within joint tissues. Cartilage has very limited ability to repair itself, and existing surgical procedures often result in the formation of fibrocartilage, which lacks the durability and mechanical properties of healthy cartilage. This project builds on scientific discoveries showing that skeletal stem cells can be directed toward true cartilage formation when exposed to specific biochemical signals delivered in a controlled manner. The research will optimize a combination of clinically established microfracture surgery with a controlled release formulation containing growth promoting and vascular modulating factors. The project will evaluate release kinetics, biological activity, and cartilage regeneration in relevant animal models such as a large animal model of osteoarthritis. Anticipated outcomes include a validated therapeutic formulation, evidence of improved cartilage quality, and foundational data supporting future translational studies. The results will advance understanding of stem cell driven tissue regeneration and establish a path toward a clinically scalable therapy. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

NSF Program Director: Henry Ahn